Современные проблемы послеоперационной лучевой терапии немелкоклеточного рака легкого


https://doi.org/10.20862/0042-4676-2015-0-2-47-57

Полный текст:


Аннотация

В обзоре рассматриваются эволюция и современное состояние проблемы послеоперационной лучевой терапии немелкоклеточного рака легкого. Рандомизированные исследования и метаанализы публикаций последних лет обосновывают целесообразность ее применения у радикально оперированных
больных с морфологически подтвержденными регионарными метастазами. Отражены также перспективы использования гипофракционирования и вопросы соотношения послеоперационной лучевой и химиотерапии при немелкоклеточном раке легкого.

Об авторах

С. Д. Троценко
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Россия
аспирант, врач-радиолог


В. М, Сотников
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Россия
д. м. н., профессор, заведующий лабораторией лучевой терапии


Г. А. Паньшин
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Россия
д. м. н., профессор, руководитель научно-исследовательского отдела инновационных технологий радиотерапии и химиолучевого лечения злокачественных новообразований


В. Д. Чхиквадзе
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Россия
д. м. н., профессор, руководитель научно-исследовательского отдела хирургии и хирургических технологий в онкологии


Список литературы

1. Trakhtenberg A.Kh. Lung cancer. Moscow: Meditsina; 1987: 302 (in Russian).

2. Davydov M.I., Polotskiy B.E. Lung cancer. Moscow: Radiks; 1994: 216 (in Russian).

3. Stilidi I.S., Ter-Ovanesov M.D. Surgical management of lung cancer. Prakticheskaya onkologiya. 2000; 3: 21–3 (in Russian).

4. Chernykh A.V. Short-term result surgical management of non-small cell lung cancer. Nauchno-meditsinskiy vestnik Tsentral'nogo Chernozem'ya. 2007; 30: 45–7 (in Russian).

5. Matthews M.J., Kanhouwa S., Pickren J., Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer.Cancer Chemother. Rep. 1973; 4 (2): 63–7.

6. Miller S.V., Tuzikov S.A., Zav'yalov A.A., Avdeev S.V., Tropin S.V., Afanas'eva A.N. et al. Analysis of complications after combined modality treatment of non-small cell lung cancer. Sibirskiy onkologicheskiy zhurnal. 2007; 4: 50–6 (in Russian).

7. Kharchenko V.P., Chkhikvadze V.D. Surgery and combined modality treatment of non-small cell lung cancer. Voprosy onkologii. 2009; 55 (4): 455–8 (in Russian).

8. Varlotto J.M., Medford-Davis L.N., Recht A., Flickinger J.C., Schaefer E., DeCamp M.M. Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81 (2): 353–9.

9. Higgins K.A., Chino J.P., Berry M., Ready N., Boyd J., Yoo D.S. et al. Local failure in resected N1 lung cancer: implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 2012; 83 (2): 727–33.

10. Kharchenko V.P., Khmelevskiy E.V. Combined and surgery treatment of lung cancer. In: III Congress materials onсologists and radiologists CIS. Rostov-na-Donu; 2004; 1: 111 (in Russian).

11. Hsu H.-C., Wang C.-J., Huang E.-Y., Sun L.M. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. Br. J. Radiol. 2004; 77: 43–8.

12. Trakhtenberg A.Kh., Kolbanov K.I. Lung cancer. Moscow: GEOTARMedia; 2012: 120 (in Russian).

13. Kharchenko V.P., Kuz'min I.V. Lung cancer. Guideline for doctors. Moscow: Meditsina; 1994: 92 (in Russian).

14. Kolbanov K.I., Trakhtenberg A.Kh., Boyko A.V., Pikin O.V., Glushko V.A. Surgical and combination treatments

15. in patients with Stage IIIAB non-small cell lung carcinoma. Onkologiya. Zhurnal imeni P.A. Gertsena. 2013; 5: 4–9 (in Russian)

16. Kolodziejczyk М., Bujko K., Michalski W., Kepka L. Incidence of isolated nodal failure in nonsmall cell lung cancer patients included in a prospective study of the value of PET–CT. Radiother. Oncol. 2012; 104 (1): 58–61.

17. Varlotto J.M., Medford-Davis L.N., Flickinger J. et al. Local and distal failure rates and pattern of recurrence in stage II–N1 surgicallyresected non-small-cell carcinoma of the lungs. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75 (3): 36.

18. Feng W., Fu X., Cai X., Yang H., Yang H.J., Wu K.L. et al. Patterns of local-regional failure in completely resected stage IIIa(n2) nonsmall cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int. J. Radiat. Oncol. Biol. Phys. 2014; 88 (5): 1100–7.

19. Warren M., Webster G., Ryder D., Rowbottom C., Faivre-Finn C. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? Clin. Oncol. 2014; 26 (8): 461–7.

20. Chkhikvadze V.D. Combined and surgery treatment of lung cancer. Dr. med. sci. diss. Moscow; 1990: (in Russian).

21. Astudillo J., Conill C. Role of postoperative radiation therapy in stage IIIa non-small cell lung cancer. Ann. Thorac. Surg. 1990; 50 (4): 618–23.

22. Green N., Kurohara S.S., George F.W. 3rd, Crews Q.E. Jr. Postresection irradiation for primary lung cancer. Radiology. 1975; 116: 405–7.

23. Choi N.C., Grillo H.C., Gardiello M., Scannell J.G., Wilkins E.W. Jr. Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1980; 6: 31–5.

24. Sawyer T.E., Bonner J.A., Gould P.M., Foote R.L., Deschamps C., Trastek V.F. et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann. Thorac. Surg.1997; 64 (5): 1402–8.

25. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998; 352: 257–63.

26. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small-cell lung cancer. Lang. Сancer. 2005; 47: 81–3.

27. Van Houtte P., Rocmans P., Smets P., Goffin J.C., Lustman-Marйchal J., Vanderhoeft P. et al. Postoperative radiation therapy in lung cancer: Acontrolled trial after resection of curative design. Int. J. Radiat. Oncol. Biol. Phys. 1980; 6: 983–6.

28. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N. Engl. J. Med. 1986; 315: 1377–81.

29. Wang M., Gu X.Z., Yin W.B. Randomised clinical trial of postoperative irradiation after surgery for non-small cell lung carcinoma. Chin. J. Radiat. Oncol. 1994; 3: 39–43.

30. Lafitte J.J., Ribet M.E., Prevost B.M., Gosselin B.H., Copin M.C., Brichet A.H. Postresection irradiation for T2N0M0 non-small cell carcinoma: A prospective, randomized study. Ann. Thorac. Surg. 1996; 62 (3): 830–4.

31. Stephens R.J., Girling D.J., Bleehen N.M., Moghissi K., Yosef H.M., Machin D. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomized trial in patients with pathologically staged T1–2, N1–2, M0 disease. Br. J. Cancer. 1996; 74 (4): 632–9.

32. Dautzenberg B., Arriagada R., Chammard A.B., Jarema A., Mezzetti M., Mattson K. et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d’Etude et de Traitement des Cancers Bronchiques. Cancer. 1999; 86 (2): 265–73.

33. Debevec M., Bitenc M., Vidmar S., Rott T., Orel J., Strojan P. et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): Randomised clinical study 1988–92. Lung Cancer. 1996; 14 (1): 99–107.

34. Mayer R., Smolle-Juettner F.M., Szolar D., Stuecklschweiger G.F., Quehenberger F., Friehs G. et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997; 112 (4): 954–9.

35. Trodella L., Granone P., Valente S., Valentini V., Balducci M., Mantini G. et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial. Radiother. Oncol. 2002; 62 (1): 11–9.

36. Marks L.B., Prosnitz L.R. Postoperative radiotherapy for lung cancer: the breast cancer story all over again? Int. J. Radiat. Oncol. Biol. Phys. 2000; 48 (3): 625–7.

37. Thames H.D. Postoperative radiotherapy of non-small cell lung cancer: a flow in the PORT metaanalysis. Progress in Radiotherapy VII. Bologna; 2002: 9–16.

38. Feng Q.F., Wang M., Wang L.J., Yang Z.Y., Zhang Y.G., Zhang D.W. et al. A study of postoperative radiotherapy in patients with nonsmall-cell lung cancer: A randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47 (4): 925–9.

39. Lally B.E., Zelterman D., Colasanto J.M., Haffty B.G., Detterbeck F.C., Wilson L.D. Postoperative radiotherapy for stage II or III nonsmall-cell lung cancer using the Surveillance, Epidemiology and End Results database. J. Clin. Oncol. 2006; 24 (19): 2998–3006.

40. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzбles- Larriba J.L. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006; 7 (9): 719–27.

41. Lally B.E., Detterbeck F.C., Geiger A.M., Thomas C.R. Jr, Machtay M., Miller A.A. et al. The risk of death from heart disease in patients with non-small cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110 (4): 911–7.

42. Billiet C., Decaluwй H., Peeters S., Vansteenkiste J., Dooms C., Haustermans K. et al. Modern postoperative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother. Oncol. 2013; 110 (1): 3–8.

43. Machtay M., Lee J.H., Shrager J.B., Kaiser L.R., Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J. Clin. Oncol.2001; 19 (19): 3912–7.

44. Matsuguma H., Nakahara R., Ishikawa Y., Suzuki H., Inoue K., Katano S. et al. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: Focusing on an effect of the number of mediastinal lymph node stations involved. Interact. Cardiovasc. Thorac. Surg. 2008; 7 (4): 573–7.

45. Mantovani C., Levra N.G., Filippi A.R., Novello S., Buffoni L., Ragona R. et al. Postoperative radiotherapy for patients with completely resected pathologic N2 nonsmall-cell lung cancer: a retrospective analysis. Clinic. Lung Cancer. 2013; 14 (2): 194–9.

46. Scotti V., Meattini I., Saieva C., Agresti B., de Luca Cardillo C., Bastiani P. et al. Post-operative radiotherapy in non-small cell lung cancer: A retrospective analysis of 175 patients. Radiother. Oncol. 2010; 96 (1): 84–8.

47. Non-Small Cell Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899 –909.

48. Remon J., Lianes P., Martнnez S., Velasco M., Querol R., Zanui M. et al. Adjuvant treatment in resected non-small cell lung cancer: Current and future issues. Crit. Rev. Oncol./ Hematol. 2013; 88 (2): 375–86.

49. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005; 352 (25): 2589–97.

50. Shen W., Jia J., Zuo Y., Pu J., Xu Y.M., Zong C.D. et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial.Radiother. Oncol. 2014; 110 (1): 120–5.

51. Keller S.M., Adak S., Wagner H., Herskovic A., Komaki R., Brooks B.J. et al. Eastern Cooperative Oncology Group. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N. Engl. J. Med. 2000; 343 (17): 1217–22.

52. Arriagada R., Auperin A., Burdett S., Higgins J.P., Johnson D.H., Le Chevalier T. et al. NSCLC Metaanalyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet. 2010; 375: 1267–77.

53. Pardo J., Mena A., Prieto I., Noe A., Luna J., Vara J. et al. Breast cancer hypofractionated radiotherapy: observational study of toxicity and outcome. Reports Pract. Оncol. Radiother. 2013; 18 (1): 57.

54. Wu J.S., Brasher P.M., El-Gayed A., Pervez N., Tai P.T., Robinson J. et al. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer. Outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction. Radiother. Oncol. 2012; 103 (2): 210–6.

55. McDonald F., Lalondrelle S., Taylor H., Warren-Oseni K., Khoo V., McNair H.A. et al. Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin. Oncol. 2013; 25 (9): 549–56.

56. Moon S.H., Cho K.H., Chung E.J., Lee C.G., Lee K.C., Chai G. et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1–2 glottic squamous cell carcinomas Results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother. Oncol. 2014; 110 (1): 98–103.

57. Izmaylov T.R., Pan'shin G.A., Datsenko P.V. The prognostic factors influencing a choice of programs of beam therapy at high-grade gliomas. Neyrokhirurgiya. 2013; 4: 26–32 (in Russian).

58. Mardynskiy Yu.S., Gulidov I.A., Ivanova I.N., Kursova L.V., Zolotkov A.G., Kudryavtsev D.V. et al. Results of continuous hyperfractionated radiotherapy in treatment of non-small cell lung cancer. Sibirskiy onkologicheskiy zhurnal. 2010; 2: 11–4 (in Russian)

59. Sharieff W., Okawara G., Tsakiridis T., Wright J. Predicting 2-year survival for radiation regimens in advanced non-small cell lung cancer. Clinical Oncology. 2013; 25 (12): 697–705.

60. Butof R., Kirchner K., Appold S., Lock S., Rolle A., Hoffken G. et al. Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer. Strahlenther Onkol. 2014; 190 (3): 263–9.

61. Krupitskaya Y., Loo B.W. Post-operative radiation therapy (PORT) in completely resected non-smallcell lung cancer. Curr. Treat. Options Oncol. 2008; 9: 343–56.


Дополнительные файлы

Для цитирования: Троценко С.Д., Сотников В.М., Паньшин Г.А., Чхиквадзе В.Д. Современные проблемы послеоперационной лучевой терапии немелкоклеточного рака легкого. Вестник рентгенологии и радиологии. 2015;(2):47-57. https://doi.org/10.20862/0042-4676-2015-0-2-47-57

For citation: Trotsenko S.D., Sotnikov V.M., Pan’shin G.A., Chkhikvadze V.D. Current problems of postoperative radiotherapy for non-small cell lung cancer. Journal of radiology and nuclear medicine. 2015;(2):47-57. (In Russ.) https://doi.org/10.20862/0042-4676-2015-0-2-47-57

Просмотров: 135

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0042-4676 (Print)
ISSN 2619-0478 (Online)